Gaithersburg, USA and Basel, Switzerland, 10 November 2020 – Altimmune, Inc., a clinical-stage biopharmaceutical company, today announced that entered into an agreement with Lonza for the manufacturing of AdCOVID, Altimmune’s next-generation, a single-dose intranasal vaccine candidate for COVID-19. Lonza is a leading global biopharmaceutical manufacturing company with facilities in Europe, North America, and South Asia.

AdCOVID is a single-dose COVID-19 vaccine candidate that has the potential to be conveniently administered via an intranasal spray. In addition to activating systemic immunity (neutralizing antibodies and T cell responses), AdCOVID stimulates a type of localized immunity called mucosal immunity, which can act to prevent both SARS-CoV-2 virus infection and transmission.

In preclinical studies, AdCOVID produced a 29-fold increase in mucosal IgA, well above the level associated with protection observed in several clinical studies from influenza, another respiratory virus.

Based on clinical experience with the Altimmune’s vaccine platform technology, AdCOVID is expected to provide durable immunity of up to a year or more following a single dose and to have an excellent tolerability and stability profile. Vaccine stability is critical for efficient vaccine deployment and AdCOVID is expected to be shipped without a cold chain and permit common refrigerated storage conditions at community-based vaccination centers without the need for specialized freezer storage.

“We are excited about the potential of our AdCOVID vaccine candidate and are actively focused on expanding our network of strategic manufacturing partners to ensure Altimmune’s commercial readiness to supply vaccine in 2021 should our clinical data support this advancement. Lonza is a tremendous partner in this mission, with deep expertise and experience in vector manufacturing and global world-class facilities capable of manufacturing AdCOVID at commercial scale.” said Dr. Vyjoo Krishnan, Vice President of Product Development, Altimmune.